ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results demonstrating efficacy benefits regardless of prior nephrectomy status with CABOMETYX ® (cabozantinib) in ...

Three-year data – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

Argentina bought $808 million in Special Drawing Rights (SDRs)from the U.S. ‌Treasury to meet an interest payment to the International Monetary Fund (IMF), local newspaper ‌La Nacion reported on ...

If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ...

Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab plus ipilimumab failed to extend OS compared with standard first-line chemotherapy for patients with ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.

Two Sealed Airtight Medical Vials Against Bright Background Front View. Findings from the phase 3 international CheckMate 901 trial called “a momentous accomplishment.” Combination therapy with ...